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We analyzed the effects of the expression of HPV 16 E6 oncoprotein variants (AA-a, AA-c, E-A176/G350,
E-C188/G350, E-G350), and the E-Prototype in global gene expression proﬁles in an in vitro model. E6
gene was cloned into an expression vector fused to GFP and was transfected in C33-A cells. Affymetrix
GeneChip Human Transcriptome Array 2.0 platform was used to analyze the expression of over 245,000
coding transcripts. We found that HPV16 E6 variants altered the expression of 387 different genes in
comparison with E-Prototype. The altered genes are involved in cellular processes related to the
development of cervical carcinoma, such as adhesion, angiogenesis, apoptosis, differentiation, cell cycle,
proliferation, transcription and protein translation. Our results show that polymorphic changes in HPV16
E6 natural variants are sufﬁcient to alter the overall gene expression proﬁle in C33-A cells, explaining in
part the observed differences in oncogenic potential of HPV16 variants.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It has been widely shown that chronic infection by High Risk
Human Papillomavirus (HR-HPV) is the main risk factor for devel-
oping cervical carcinoma (CC) and its precursor lesions (Münger et
al., 2004). Genotype 16 of the HR-HPV is the most common in
cervical carcinoma worldwide (Crosbie et al., 2013; Obeidat et al.,
2013), and its oncogenic potential is mainly related to the action of
oncoproteins E6 and E7. These oncoproteins have the ability to bind
several cellular proteins and interfere with fundamental processes
which promote cervical carcinogenesis, such as apoptosis, cellInc. This is an open access article u
ancingo, Gro. México, 39090.
capala-Gómez),
),differentiation, adhesion, cell cycle, and immune response (Wise-
Draper and Wells, 2008; Narisawa-Saito and Kiyono, 2007; Pim and
Banks, 2010; Moody and Laimins, 2010).
Several studies have suggested that HPV 16 variants may con-
tribute to cancer development (Xi et al., 2007). Genetic studies have
shown natural amino acid variants of HPV16 that are classiﬁed
according to the polymorphic changes in the E6 gene and the LCR
region (Cornet et al., 2012). The reference HPV 16 genome was
sequenced in 1985 (Seedorf et al., 1985) and many variants have
been found since that time. HPV 16 variants have been classiﬁed
into four major lineages (European-Asian, African 1, African 2 and
Asian-American/North-American) and nine sublineages (Cornet et
al., 2012). The presence of polymorphisms that generate amino acid
changes in the E6 oncoprotein has been shown. T350G, a common
polymorphism in European variants, causes a leucine to valine
change (L83V); T178G, common in Asian variants, leads D25E;
G145T, common in Asian American and North American variants,
leads Q14H; C143G, common in African variants, leads Q14D
(Huertas-Salgado et al., 2011). Polymorphisms frequency depends
on the population studied (Xi et al., 2007, 2006; Cornet et al., 2012;
Tornesello et al., 2011; Pillai et al., 2009).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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shown that even in the same country its distribution is different
depending on the region analyzed. Our laboratory in southern
Mexico has recently reported that the risk of developing cervical
cancer in women infected with AA-a, AA-c, E-G350, E-C188/G350
and E-A176/G350 variants ranges from 69.01 (AA-a) to 10.48 fold
(E-C188/G350), compared to women infected with HPV16 E-
Prototype (reference HPV 16 sequence) (Ortiz-Ortiz et al., 2015).
Some studies have analyzed the effect of HPV16 E6 oncoprotein
variants overexpression in primary cultures of keratinocytes and
found that variants differ in their ability to induce serum/calcium-
resistant colonies and down-regulation of p53 and Bax (Asadurian
et al., 2007), affecting several important cellular processes,
including differentiation, apoptosis (Zehbe et al., 2011, 2009),
immortalization, transformation (Richard et al., 2010; Niccoli et al.,
2012), migration and metastasis (Niccoli et al., 2012). Thus,
experimental evidence supports the theory that intra-typical var-
iations can affect the carcinogenic potential of HPV16, posed sev-
eral years before (Bernard et al., 2006). Even though the effect of
HPV16 E6 oncoprotein variants on processes related to carcino-
genesis has been demonstrated, there are only a few studies that
analyze their effect on the transcriptome at a global level. Jang
et al. (2011) reported that the Asian variant (D25E) increases the
expression of nine genes (ZMZ1, RPL23, MAPK4, RPL31, RARS,
LAMB3, HSPA14, AIFM2, and IFRD1) and decreases the expression
of ﬁve genes (UBC, RPS9, HLA-a, HLA-B, and ROCK2). Even if the
speciﬁc functions of these genes in cervical oncogenesis remain to
be elucidated, they conclude that E6 D25E might have a unique
oncogenic role in cancerous transformation. In another study, a
panel of 84 selected cellular genes involved in transformation and
tumorigenesis was analyzed in primary human foreskin kerati-
nocytes transduced with HPV 16 E6 and E7. They found that
E-Prototype, AA, and E-G350 variants signiﬁcantly affected the
expression of p16, MMP, MMP2, S100A4, SERPINE1, FOS, and
MDM2. Furthermore, they found that upregulation of IL8 andR
el
at
iv
e 
E6
 m
R
N
A
 e
xp
re
ss
io
n
C3
3-A M
oc
k
E-
Pr
oto
typ
e
AA
-a
0.0
0.5
1.0
1.5
2.0
2.5
Actin
E6^GFP
C33-A AE-PrototypeC33-AMock
Fig. 1. Expression of HPV16 E6 variants in C33-A cells. (a) Relative expression of E6 mRNA
time PCR). Despite the differences observed, no statistically signiﬁcant difference (Stude
HPV16 variants in C33-A cells analyzed by Western blot using anti-GFP antibody. IncreaMAP2K1 were speciﬁcally detected in AA and E-350G infected
cells, respectively, independently of passages (Sichero et al., 2012).
To our knowledge, there are no studies that analyze the global
gene expression proﬁle at the transcriptional level induced by the
HPV16 E6 oncoprotein variants. We have previously reported the
frequency of HPV16 variants in southern Mexico and found that the
most common variants are E-G350, followed the E-Prototype,
E-C188/G350, AA-a, AA-c, and E-A176/350. Furthermore, the AA
variants of HPV16 were 15-fold more prevalent than E-Prototype in
cervical carcinoma. Therefore, the aim of our study was to analyze
the effect of E6 oncoprotein expression from AA-a, AA-c, E-G350,
E-A176/G350 and E-C188/G350 variants in global gene expression in
an in vitro model in comparison with the E-Prototype, in order to
provide a better understanding of the previously observed differ-
ences in their ability to promote immortalization, transformation,
and migration. We found that HPV16 variants altered the expres-
sion of 387 different genes compared with the E-Prototype, and that
there is a differential proﬁle of genes altered by each HPV16 variant
in C33-A cells. Interestingly, the altered genes are involved in cel-
lular processes associated with the development of cervical cancer
such as adhesion, angiogenesis, apoptosis, cell migration, tyrosine
kinase signaling pathway, and proliferation.Results
Stable HPV16 E6 oncoprotein variants expression
The E6 oncoprotein gene of the HPV16 variants analyzed were
cloned into the expression vector pEGFP-N1 to generate a fusion
protein E6^GFP. C33-A cells were stably transfected and selected by
sorting to have greater than 90% purity (data not shown). E6
mRNA was quantiﬁed by qRT-PCR to conﬁrm the expression of the
transcript. We found that the level of E6 mRNA is similar in all the
analyzed groups, and despite the differences observed, no statis-
tically signiﬁcant difference in expression was found whenAA
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Fig. 2. HPV16 E6 oncoprotein variants differentially alter expression of genes in C33-A cells vs. E-Prototype. The Venn diagrams show unique and common differentially
expressed genes (a fold change Z1.5 and r1.5) between cells expressing the E6 oncoprotein of E-Prototype and E-6 variants. The p-value was calculated with FDR, p-
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Fig. 3. Global expression proﬁle induced by the HPV16 E6 oncoprotein variants
expression vs. E-Prototype. E6 oncoproteins from HPV16 variants differ in their
capacity to upregulate and downregulate genes in C33-A cells. The AA-c and
E-G350 variants had the most genes altered (111 vs. 118 and 109 vs. 23
respectively).
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expression of the E6 protein by Western blot using an anti-GFP
antibody. As shown in Fig. 1b, cells expressing the E6 oncoprotein
of the variant E-A176/G350 express more than all other variants
despite having similar levels of messenger. The other variants
showed slight differences in E6 oncoprotein expression.
HPV16 E6 oncoprotein variants differentially alter expression genes
To assess the global expression proﬁle in C33-A cervical cancer
cells stably transfected with E6 oncoprotein of ﬁve different var-
iants of HPV16, total RNA was evaluated with the Human Tran-
scriptome Array 2.0 platform (Affymetrix). We deﬁned the global
gene expression proﬁle induced by the expression of the E6
oncoprotein variants focusing our attention on the coding tran-
scripts present in the array (Fig. 2) The comparison of the speciﬁc
gene expression proﬁles established by the variants reveals that
the most dramatic changes were observed in the AA-c and E-G350
ones (229 and 132 respectively altered genes). The E6 oncoprotein
expression of the E-Prototype vs C33-A wild type alters the
expression of 266 genes; additionally, the comparison between
the variants and E-Prototype overlaps with some common altered
genes but with a different expression magnitude reﬂected in a
different fold change (Fig. 2, Supplementary Table S1). On the
other hand, we found that 436 genes were regulated exclusively
by HPV16 E6 variants of which 278 were upregulated and 158
were down regulated (Fig. 3). Of the 436 genes mentioned, 387
were unique genes altered by E6 variants and 49 of them are
overlapped between variants (Supplementary Fig. S1, Supple-
mentary Table S2).
Genes altered by effect of HPV16 E6 variants expression are involved
in cancer related processes
To classify differentially expressed genes according to their
function, we performed an analysis using gene ontology. We found
that the altered genes are involved in several processes related to
cancer such as adhesion, angiogenesis, apoptosis, cell cycle, differ-
entiation, migration, proliferation, and cell signaling. The cellular
processes with the largest number of genes altered were cell sig-
naling (20.3%), transcription (16.7%) and adhesion (14.6%) (Fig. 4).
The genes were classiﬁed according to their cellular process andfold change in relation to the E-Prototype. We did not ﬁnd a gene
expression pattern characteristic of the phylogenetic branch var-
iants (AA or European). However, we found some genes (ARID5B)
that were upregulated by the expression of E6 from AA-c and E-
G350 variants and IGF1R and ROR1 by E6 from AA-a and E-G350
variants. Furthermore, we also found genes such as EPHA5,
CTNNA2, and SYNE1 that decrease its expression by the effect of the
divergent E6 variants AA-c and E-G350 (Supplementary Table S3).Functional enrichment analysis
In order to highlight the most relevant biological processes asso-
ciated with the expression proﬁle established by each E6 variants we
performed an enrichment analysis using the DAVID database, which
allowed us tomeasure the relationships among the different annotation
terms. The enrichment analysis showed that AA-c, E-C188/G350 and E-
G350 variants were those that showed more enrichment in processes
such as angiogenesis, cell junctions, migration, immune response,
apoptosis, cell division, proliferation, and activation of kinases; as well
as in signaling pathways TGF-beta and cell junction/cadherin/WNT.
Genes of TGF-beta signaling pathway like TGFBR2, BMPR1B, THBS1, and
BMP5, were altered by AA-c variant while the genes EZR, PVRL3, CDH2,
NID1, PCDH9, ROBO2 and PCDHB15 of cell junction/Cadherin/WNT
signaling were altered only by E-G350 variant (Fig. 5, Supplementary
Table S4).
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Fig. 4. Gene ontology-based biological process pathways related to cancer. The
genes that were differentially expressed by E6 of HPV16 variants were grouped
according to their function in biological processes for the development and
maintenance of cancer. Cellular processes more affected were cell signaling and
adhesion. Both upregulated and downregulated genes are shown. For the analysis
were not included the overlapping genes between E-Prototype and HPV 16
variants.
A.E. Zacapala-Gómez et al. / Virology 488 (2016) 187–195190Validation of the microarray data
To validate the microarray data we selected a group of genes
involved in cell adhesion (AMOTL1, CDH2, CDH6, CDH9, COL11A1,
NID1, NRCAM, and CALCR), which were validated by qRT-PCR analysis.
As shown in Table 1, the results for most of the genes analyzed were
consistent with the microarray data. Among the analyzed genes,
COL11A1, CALCR and NRCAM were the most up-regulated. Expression
of CDH2 (E-G350), CDH6 (AA-c), CDH9 (AA-a), COL11A1 (AA-a),
NRCAM (AA-a) and CALCR (AA-c) was observed by qRT-PCR when the
oncoprotein HPV16 E6 variants were expressed in comparison to the
E-Prototype.Discussion
In this study, we used a global approach to analyze the effect of
E6 HPV16 oncoprotein variants expression AA-a, AA-c, E-A176/
G350, E-C188/G350, and E-G350 in comparison with the E-Prototype transfected in the C33-A HPV-negative cervical cancer
cell line on the transcriptome. It has been reported that the C33-A
is a cell line containing mutations in pRB and p53 genes, so they do
not need the carcinogenic effects of E6 and E7 of the HR-HPV
oncoproteins (Scheffner et al., 1991). Therefore, this model allows
the study of the effects of E6 oncogene in an established cell line.
The variants analyzed were isolated from HPV16-infected cervical
cancer or precursor lesions samples of women from southern Mexico.
Our results indicate that there is a speciﬁc gene expression proﬁle of
each variant, and that most of these genes are involved in oncogenic
processes such as adhesion, proliferation, apoptosis, migration and cell
projection. To our knowledge, this is the ﬁrst study that compares the
overall transcription proﬁle in cervical cancer cells due to the
expression of the E6 oncoprotein of ﬁve variants of HPV16 and E-
Prototype. Our results provide evidence that could partially explain
the different behavior regarding the oncogenic potential of each var-
iant, as has previously been suggested.
Epidemiological studies suggest that variants of E6 HPV16 have
different oncogenic potentials (Mosmann et al., 2015; Qmichou et al.,
2013; Tornesello et al., 2011; Xi et al., 2007; Fontecha et al., 2015),
mainly based on the distribution and frequency in cervical cancer and
precursor lesions. Moreover, some experimental studies show that
natural intratypic variability in E6 gene variants of the HPV16 are
sufﬁcient to alter cellular functional activities induced by E6 such as
resistance to serum/calcium differentiation, extension of the life span
of primary human keratinocytes and reduction of the expression
levels of p53 and Bax in human immortalized keratinocytes
(Asadurian et al., 2007), apoptosis (Zehbe et al., 2011, 2009), and
transformation and immortalization of human keratinocytes (Sichero
et al., 2012). However, the mechanisms responsible for these altera-
tions, as well as genes involved in its regulation, have not been elu-
cidated. Unlike the studies in primary human keratinocytes that only
allow the study of cell transformation events, the C33-A model allows
us to study the effects of E6 oncogene independent of p53 in an
established cancer cell.
All variants tested in this study have an L83V amino acid
change (at the carboxyl terminus domain of E6) compared to E6
from E-Prototype. Various in vitro studies have reported that this
amino acid change gives E6 greater efﬁciency in the degradation of
p53, Bax and binding to E6AP, higher ability to abrogate PHFKs
differentiation induced by serum and calcium, but less efﬁcient
binding to hDlg (Asadurian et al., 2007; Stöppler et al., 1996;
Lichtig et al., 2006), immortalization and transformation abilities
(Richard et al., 2010) and regulation of tumorigenesis by the
NOTCH and RAS signaling pathways (Chakrabarti et al., 2004). We
have previously reported that the E-G350 (L83V) is the most
common variant in our region, but it is not the most associated
with the development of cervical carcinoma (Ortiz-Ortiz et al.,
2015). Interestingly, the expression of the E6 oncoprotein from E-
G350 (L83V) variant modulates the expression of more genes than
other European variants and AA-a in C33-A cells (Fig. 2). The
modulation of many genes may confer some advantages that relate
to its high prevalence, however, the function of regulated genes is
likely also important to confer oncogenic potential.
In addition to the L83V change, four of the ﬁve variants studied
show other amino acid changes. In the branch AA, the AA-a variant
has two more changes (Q14H /H78Y), while the AA-c variant has
three (Q14H/I27R/H78Y) (Huertas-Salgado et al., 2011). It has
recently been reported that AA E6 has enhanced abilities over E-
Prototype E6 in driving the infected epithelium toward tumor-
igenesis in a three-dimensional keratinocyte model (Jackson et al.,
2014). Our results show that expression of the E6 oncoprotein of
variant AA-c (Q14H/I27R/H78Y/L83V) modulates expression of
more genes compared to the other variants (Fig. 2). However, E6
AA-a variant only modiﬁes the expression of 22 genes, although
the two variants differ only in one residue (I27R). Because the
Fig. 5. Enrichment score of biological processes modulated by HPV16 E6 variants. Pathway enrichment analysis reveals over-representation or under-representation of
oncogenic pathways for the HPV variants based in the differentially expressed genes. The plot shows enrichment scores and percentage of involved genes according to the
enrichment cluster analysis from DAVID. Upregulated (red), downregulated (blue). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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Table 1
Validation of microarray data by RT-qPCR.
Genea Fold changeb determined by:
Microarrays qPCR
AA-a AA-c E-G350 AA-a AA-c E-G350
AMOTL1 – 1.6 – – 2.72 –
CDH2 – – 1.65 – – 2.35
CDH6 – 1.69 – – 2.95 –
CDH9 1.9 – – 5.97 – –
COL11A1 6.01 – – 19.86 – –
NID1 – 2.28 7.6 – – 12.62
CALCR – 61.23 – – 120.88 –
All comparisons were done between E-Prototype vs. E6 variants.
a AMOTL1: Angiomotin Like 1, CDH2: Cadherin 2, CDH6: Cadherin 6, CDH9: Cadherin 9, COL11A1: Collagen, Type XI, Alpha 1, NID1: Nidogen-1, CALCR: Calcitonin
Receptor. The full names of the genes were taken from the GeneCards data base. (–) no alteration in the expression when compared to HPV E6 E-prototype.
b The values shown are means of three independent experiments.
A.E. Zacapala-Gómez et al. / Virology 488 (2016) 187–195192importance of this amino acid on HPV16 E6 oncogenicity has not
been studied, we can only suggest that its presence regulates the
number of genes compared to E6 from AA-a variant, but a possible
mechanism is not currently available in the literature. This result
was unexpected since AA-a variant shows the highest association
with the development of cervical carcinoma in our population
(Ortiz-Ortiz et al., 2015), but it is possible that the small number of
genes altered by AA-a variant is enough to establish tumorigenic
pathways.
The variants of the European branch E-A176/G350 that presents an
extra amino acid change at the D25N residue, and E-C188/G350 that
has a modiﬁcation in the residue E29Q (both additional changes to
L83V) compared to E-Prototype, also differ in their ability to alter gene
expression proﬁles. Our results shown that the E6 oncoprotein of
E-A176/G350 variant modulates the expression of few genes com-
pared with the other variants. It is surprising that only one gene is
altered by this E6 variant and E-Prototype, however it is hard to
explain because there are no studies that analyze the role of D25N on
E6 oncoprotein function. However, in a previous study we found that
this European variant is the most closely related with the develop-
ment of cervical cancer in our region (Ortiz-Ortiz et al., 2015). Inter-
estingly, we observed that cells transfected with the E-A176/G350
variant expresses more protein than all others variants despite having
similar levels of messenger. Although, it is difﬁcult to explain this
phenomenon, we consider that post-transcriptional regulation
mechanism, such as alternative splicing, could inﬂuence this behavior,
however this fact could be a limitation of this study. It has been
reported that mutations in a single nucleotide in the HPV 16 E6 gene
are sufﬁcient to alter the splicing pattern (López-Urrutia et al., 2012),
and therefore may generate different amounts of messenger useful to
be translated to E6. Currently our group is investigating this
hypothesis.
Our analysis shows that there is not an apparent pattern in
terms of transcriptional regulation that identiﬁes each phyloge-
netic branch (European and Asian-American) since the behavior in
the genes and the number of modulated transcripts varies widely.
Our results identiﬁed a total of 436 altered genes by the
expression of E6 variants. According to our gene ontology analysis,
the cells expressing HPV E6 oncoprotein of E-C188/G350 variant
mainly promotes the upregulation of cell proliferation and acti-
vation of kinase activity, while the cells expressing the E6 onco-
protein of AA-a, AA-c and E-G350 variants favor cell–cell adhesion,
protein kinase activity, and tyrosine kinase signaling pathway
(Figs. 4 and 5).
This differential behavior might be responsible for the biolo-
gical role of the variants in cervical cancer. Previous reports have
analyzed the functional activity of the AA and E-G350 E6 variants,indicating that both have more oncogenic potential compared to
the E-Prototype (Sichero et al., 2012; Zehbe et al., 2009; Jackson et
al., 2014). However, this is the ﬁrst report describing the in vitro
analysis of the effect of E6 oncoprotein expression from AA-a, AA-
c, E-C188/G350, E-A176/G350 and E-G350 variants in global gene
expression proﬁle in a cervical cancer cell line. Our results indicate
that the additional amino acid changes in E6 variants could be
sufﬁcient to confer different oncogenic potentials; this hypothesis
can be validated with functional analysis in future studies. How-
ever we can not overlook the possibility that variations in other
HPV proteins are likely involved in the oncogenic potential of each
variant, because it has been shown that the E7 oncoprotein is
necessary for cell transformation (Togtema et al., 2015).
Among the most important genes altered as a result of the
expression of the E6 oncoprotein of variants is cadherin, which is
involved in cellular interactions through the formation of inter-
cellular connections or adherent junctions (Takeichi, 1990).
Because metastasis begins with local disruption of cell–cell inter-
action, changes in the expression of cadherins play a critical role in
the progression of tumors (Frixen et al., 1991; Vleminckx et al.,
1991). We observed that the C33-A cells expressing the E6 onco-
protein of E-G350 variant increase the expression of cadherin 2
(responsible for transendothelial migration), E6 of AA-c increase
cadherin 18 and 6, and E6 of AA-a increase cadherin 9
(Tables 1 and S3). Aberrant expression of these genes could be a
late effect of the E6 oncoprotein in tumor cells enabling it to
advance in their degree of malignancy. Interestingly, cadherin
6 overexpression is associated with tumor growth and metastases
in kidney cells (Shimazui et al., 2004). On the other hand, we
found that factor receptor insulin-like growth 1 (IGF1R) is over-
expressed by effect of E6 AA-a and E-G350 variants. Previous
studies have shown a role for IGF1R in cellular radio-resistance in
cervical carcinoma cell lines (Kaneko et al., 2007). Moreno-Acosta
et al. (2012) found that in 34% of patients with HPV16-positive
cervical cancer overexpression of IGF1R occurs. The over-
expression of IGF1R is a predictive marker for patients undergoing
radio therapy because overexpression of this receptor confers 28.6
times greater risk of treatment failure.
It has been reported that high risk HPV E6 interacts with sev-
eral cellular proteins such as transcription factors, ubiquitin liga-
ses, signal transduction proteins, scaffolding proteins, calcium
binding proteins, apoptosis inducers, among others (Mantovani
and Banks, 2001). Therefore, amino acid changes in HPV E6 variant
proteins may alter the binding with its target proteins, resulting
transcription pattern changes. On the other hand, we do not know
if the binding with PDZ proteins could be affected, because the E6
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considered a limitation of the study.
It is interesting that there are many differences between E6 HPV 16
variants and the E-Prototype and it is still a big question how these
differences will lead us to understand the mechanisms involved.Conclusion
In summary, our results provide evidence that polymorphisms in
the HPV16 E6 gene that lead to amino acid changes in the protein are
enough to modulate the transcription of speciﬁc genes in each variant.
For the ﬁrst time, the comparison of global gene expression proﬁle
modulated by the expression of E6 oncoprotein of the ﬁve HPV16
variants more frequent in our region is reported. Each variant appears
to have its own molecular signature that may confer an advantage in
some cell functions but may limit it in others. Therefore, future
functional studies based on the proﬁle of genes altered for each var-
iant are needed to analyze the mechanisms that are involved and to
determine their signiﬁcance in tumor biology.Materials and methods
HPV16 E6 gene variants isolation from cervical samples
The DNA biobank of the Molecular Biomedicine Laboratory at
the School of Chemistry and Biology of the Autonomous University
of Guerrero in Chilpancingo, Guerrero, Mexico, was searched for
cervical DNA samples with E-G350, E-A176/G350, E-C188/G350,
AA-a and AA-c HPV16 E6 variants, and HPV16 E-Prototype. These
samples came from cervical scrapings of women from southern
Mexico that had given prior informed consent PCR was performed
to amplify HPV16 E6 gene region (nucleotides 48–622) with pri-
mers HPV16-F048/HPV16-R622 (Casas et al., 1999). To conﬁrm the
identity of each variant, each PCR product was sequenced in
automated ABI Prism 310 Genetic Analyzer (Applied Biosystems,
Foster City, CA). The sequences obtained were aligned with the
reference sequence of HPV16 E6 gene (NC_001526.2) as we have
previously reported (Ortiz-Ortiz et al., 2015).
Cloning HPV16 E6 variants into pEGFP-N1vector
To construct the pE6/EGFP-N1 vector, the sequence of HPV16
E6 gene variants AA-a, AA-c, E-A176/G350, E-C188/G350, E-G350,
and E-Prototype was ampliﬁed by PCR using the primer pair E6-
beginHindIII and E6-endBamHI (Del Moral-Hernández et al., 2010)
to include restriction sites and eliminate the stop. All constructs
were cloned in frame at the BamH1 site restriction of the pEGFP-
N1 vector (Clontech Laboratories, Inc). The E6 carboxy terminus
was connected to the GFP protein by a seven-amino acid peptide
that resulted from the translation of the linker sequence (21 nt)
between the BamH1 site and the start codon of GFP (Del Moral-
Hernández et al., 2010). Constructs were veriﬁed by sequencing
using a Big Dye Terminator Ready Reaction Kit in the ABI PRISM
310 Genetic Analyzer System (Perkin-Elmer, Branchburg, NJ, USA).
Cell culture and stable transfection of C33-A cells
The cervical carcinoma cell line C33-A used in a previous report
(Del Moral-Hernández et al., 2010), was grown at 37 °C in 5% CO2,
using MEM supplemented with 10% fetal bovine serum (Gibco, Life
Technologies, USA), 100 U/ml penicillin and 100 mg/ml strepto-
mycin. Cells were stably transfected using the standard calcium
phosphate co-precipitation method (Jordan and Wurm, 2004).
Brieﬂy, cells were grown for 24 h, transfected with 10 mg of eachDNA construct and selected in MEM medium supplemented with
500 mg/ml G418 (Invitrogen, Corp.). After 4 weeks of selection,
GFP-positive cells were sorted by FACS (FACS Calibur, BD, Moun-
tain View, CA, USA) to obtain a purity of greater than 90%. The
transfected cells were not cloned, but each experiment was
repeated in at least three different independent assays.
Gene expression analysis
Total RNA was extracted from non-transfected C33-A cell cul-
tures, stably transfected cell cultures and cells transfected with an
empty vector, using Trizol (Invitrogen) and following the manu-
facturer’s protocol. Equimolar concentrations of total RNA from
3 independent experiments were pooled, a total of 2 biological
pools (n¼3) per condition were made. The RNA quality was
evaluated by capillary electrophoresis (Agilent 2100 Bioanalyzer,
Agilent Technologies), only RNA samples with an RNA Integrity
Number greater than 8.0 were further processed for microarray
analysis. 200 ng of RNA from each experimental condition were
evaluated in the in the Gene Chip Human Transcriptome Array
(HTA) 2.0 (Affymetrix) to deﬁne the whole transcriptome expres-
sion proﬁles according to the manufacturer's protocol (See list of
the differentially expressed genes in GEO ID: GSE73761). Brieﬂy,
the cDNA synthesis, ampliﬁcation, and gene expression proﬁling
were done with the WT PLUS Reagent Kit for fresh samples
(Affymetrix, Santa Clara, USA). Wash and stain processes were
performed with the Genechip hybridization wash and stain kit in
the GeneChip Fluidics Station 450 (Affymetrix, Santa Clara CA,
USA). The probe arrays were scanned using The GeneChip Scanner
3000 7G (Affymetrix, Santa Clara CA, USA). Array signal intensities
were analyzed with the Affymetrix expression console. Brieﬂy, raw
data probes were normalized using robust multiarray analysis
(RMA) for the background correction and quantile algorithm. To
deﬁne the differential expression proﬁles within the different
variants, a two-way Anova was performed in the Affymetrix
Transcriptome Analysis Console (TAC) software. Genes with a fold
change Z1.5 or r1.5 and with a p-value r0.05 were con-
sidered signiﬁcantly altered between the conditions. To remove
the possible bias associated to the transfection procedure, we
removed those genes that were signiﬁcantly altered between non-
transfected C33-A vs. C33-A transfected with the empty vector. To
identify those biological processes altered by the E6 variants, we
used DAVID software (http://david.abcc.ncifcrf.gov/summary.jsp),
a bioinformatic tool for identiﬁcation of the most relevant gene
ontology process associated with the altered genes. Any process
with an enrichment score greater than 0.5 was considered
signiﬁcant.
Real time RT-PCR
Total RNA was extracted from cultures of C33-A non-transfected
cells, C33-A transfected with E6 from HPV16 variants, and C33-A
transfected with empty vector, using Trizol (Invitrogen) following the
manufacturer's instructions, then treated with DNase I, and ﬁnally
reverse-transcribed using oligo-dT primers. cDNA synthesis was done
as described according to the manufacturer’s instructions with
SuperScript
s
III Reverse Transcriptase enzyme (Invitrogen). To amplify
the E6 transcripts the primer pair E6-F083 and E6R223 (Del Moral-
Hernández et al., 2010) was used. PCR was performed using 100 ng/ml
of the cDNA and 0.5 mM of each primer. Real time PCR experiments
were performed using the Power SYBRGreen PCR Master Mix and a
Real Time ABI-PRISM 7500 SDS (Applied Biosystems). The ampliﬁca-
tion protocol was 10 min at 95 °C, followed by 40 cycles of 15 s at
95 °C, 60 s at 60 °C for annealing. We used the primer pair GAPDH-
F0855/GAPDH-R1163 to amplify GAPDH (Truong et al., 2006) as
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both negative and positive controls were included in each reaction.
For genes that were validated we used TaqMan (R) Gene
Expression Master Mix (Applied Biosystems) probes AMOTL1
(Hs00982921_m1), CDH2 (Hs00983061_m1), CDH6 (Hs010-
26788_m1), CDH9 (Hs00940349_m1), COL11A1 (Hs01097-
681_m1), NID1 (Hs00915876_m1), CALCR (Hs01016885_m1) and
GAPDH (Hs99999905_m1). Each gene-speciﬁc cDNA was quan-
tiﬁed in triplicate and mRNA ratios relative to the housekeeping
gene GAPDH were calculated. The relative quantiﬁcation of
mRNA was analyzed using method 2ΔΔCt, and the means
obtained from the triplicates are shown.
Western blot
Cells cultures with 80–95% conﬂuence were treated with 10 mM
proteasome inhibitor (Z-Leu-Leu-Leu-al) MG132 (Sigma-Aldrich) for
6 h. Protein extraction was performed using the ProteoJET CellTM
Mammalian Cell Lysis Reagent (Thermo Scientiﬁc) kit following 2
PBS washes. Total protein (50 mg) was mixed with Laemmli sample
buffer, boiled, separated by 12% SDS-PAGE, and transferred to a PVDF
membrane (Perkin Elmer). Anti-GFP primary (Rockland) and second-
ary anti-goat-HRP antibodies were used (Santa Cruz). Anti-β-actin and
anti-mouse-HRP were used as a loading control (donated by Dr. JM
Hernández, CINVESTAV-IPN). Visualization was done on the MP Che-
miDoc Imaging System (Bio Rad).Acknowledgments
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